



Professor R.K. KOHLI PhD

FNA, FASc, FNASc, FNAAS, FRS-C, FRS-B, FBS, FNESA
Former JC Bose National Fellow (2-terms)
Certified Senior Emeritus Ecologist, ESA, USA
Former Vice-chancellor, Central University of Punjab

Vice-Chancellor

Amity University Punjab, -
Mohali- 140306, India
rkkohli@pb.amity.edu
rkkohli45@yahoo.com
www.rkkohli.com

AUP/VCO/OW/112/2024

dated: 16-Aug-2024

Nomination- DR Javed Agrewala

Dr. Agrewala is an eminent scientist whose achievements resonate nationally and internationally. His groundbreaking work has earned him the highest honors in Indian science, including the prestigious **Shanti Swarup Bhatnagar Prize**. He is a Fellow of India's three premier science academies: the **Indian National Science Academy**, the **Indian Academy of Sciences**, and the **National Academy of Sciences India**. Additionally, he has been recognized with the **JC Bose Fellowship**, the **Bill & Melinda Gates Award** for High-Quality Research at the Vaccine Congress in Shanghai, and the **National Biosciences Award**, among other distinguished accolades.

Dr. Agrewala's remarkable research contributions have also led to invitations as a Visiting Scientist at renowned institutions such as the Royal Postgraduate Medical School, UK and the Trudeau Institute, USA. His influential findings have been published in top-tier scientific journals, further cementing his status as a leading scientist in his field.

His innovative findings have been published in **high-impact journals** like **Gut Microbes**, **Aging Cell**, **Autophagy**, **Cell Mol Life Sci**, **PloS Pathogens**, **Trends Mol Med**, **J Infect Dis**, **J Biol Chem**, **J Immunol**, **J Trans Med**, **J Proteome Res**, **J Innate Immunity**, **Eur J Immunol**, etc. and endorsed by scientists worldwide by **high citations: 16002**, **h-index: 39**, **i10-index: 96**. He has been **"granted several national and international patents"**. Notably, he has transferred a **technology worth "USD 3 million"** to the Nostrum Pharma Company, USA.

Dr. Agrewala's work has significantly progressed in vaccine development, particularly for tuberculosis. His epitope-based chimeric vaccine overcomes the limitations of the BCG vaccine, providing enhanced and lasting immunity. This innovative vaccine, advancing to clinical trials under the Indian Council of Medical Research, has garnered attention from global experts, including Prof. DC Jackson of the University of Melbourne and Prof. P Andersen of the Statens Serum Institute, Denmark.

Additionally, Dr. Agrewala has developed a novel vaccine against morphine addiction, inducing high-affinity anti-morphine antibodies that clear morphine from the bloodstream and brain. This vaccine reduces addiction-related μ -opioid receptors and dopamine genes while boosting memory CD4 T-cells and B-cells. Dr. Agrewala's group has also discovered Caerulomycin A as an effective immunosuppressive agent for autoimmune diseases and developed a host-directed therapy that improves TB drug efficacy and combats drug resistance. Their research into gut microbes has unveiled new insights into TB resistance, potentially leading to novel adjunct therapies for improved treatment.

Given Dr. Agrewala's exceptional achievements and the profound impact of his work on advancing medical science, his contributions are highly revered within the scientific community. I enthusiastically and strongly recommend/endorse Dr. Agrewala for the Sun Pharma Science Foundation Research Awards 2024 in Medical Sciences (Basic Research), recognizing his outstanding dedication and transformative impact on the field.

R K Kohli
Vice-chancellor